Company Overview and News

Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018

5h globenewswire
GERMANTOWN, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal first quarter ending February 28, 2018.
Upvote Downvote

Gilead: Yescarta Faces Unforeseen Hurdles

2018-04-16 seekingalpha
In hospital costs for GILD's Yescarta could be as high as $1MM. The high costs could limit the number of patients who can afford Yescarta.
Upvote Downvote

Portfolio Review: Continued Market Outperformance In Q1 2018

2018-04-15 seekingalpha
Integrated BioSci Investing outperformed all benchmarks since inception as we’ve compounded at the 30% rate. For the same period, the XBI, DOW, and IBB procured 27%, 15%, and 9%, respectively.
Upvote Downvote

Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

2018-04-12 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) is the latest company to join the ongoing acquisitions spree in the biotech sector. The company recently announced that it will acquire Sweden-based Wilson Therapeutics.
Upvote Downvote

Cellectis Snags $164 Million in IPO to Advance CAR-T Programs

2018-04-11 biospace
During the J.P. Morgan Healthcare Conference Andre Choulika, chief executive officer of France-based Cellectis told BioSpace he was excited about the future of CAR-T therapies and where his company fits into the space.
Upvote Downvote

Evaluating Risk: Gilead Sciences, Biogen and Celgene

2018-04-06 biospace
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks. Brian Abrahams, an analysts with RBC, recently examined the three companies in a research note to clients. Here’s a look.
Upvote Downvote

5 Best Stocks That IPO’d in Q1

2018-04-05 investorplace
The markets may be volatile – but this hasn’t stopped IPOs. According to Renaissance Capital, the first quarter saw the largest amount raised by newly public companies since 2014. In all, 43 companies raised a hefty $15.6 billion.
Upvote Downvote

Be Ahead Of The Curve With Gilead Sciences

2018-04-05 seekingalpha
Gilead has had a rough couple of years with the precipitous fall of their HCV franchise.
Upvote Downvote

4 Healthcare Megatrends for Investors

2018-04-04 zacks
When you think about investing to powerfully grow your money into the future, what giant long-term trends come to mind first?
Upvote Downvote

Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

2018-04-04 zacks
Pfizer Inc. (PFE - Free Report) announced that it has formed an alliance with private biotech, Allogene Therapeutics, to expedite the development of its allogeneic CAR-T therapy.
Upvote Downvote

Former Kite Pharma Execs Launch Allogene Therapeutics with Pfizer Support and $300 Million

2018-04-04 biospace
Pfizer Inc., based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
Upvote Downvote

Atlanta Wi-Fi, Snapchat video hangouts, SF biotech firm teams with Pfizer

2018-04-03 sfgate
Travelers at the world’s busiest airport can once again use free Wi-Fi after a cyberattack last month. The system at Hartsfield-Jackson Atlanta International Airport had been down since a ransomware attack hit Atlanta’s computer network on March 22. Officials say the attack didn’t affect safety at the airport, but the Wi-Fi and flight information systems were taken down as a precaution.
Upvote Downvote

An Integrated BioSci Report On Alpine Immune Sciences: A Stellar Next-Generation Immunotherapy Innovator

2018-04-01 seekingalpha
Leveraging on its unique technology platforms, the company is developing an enriched pipeline of next-generation immunotherapies.
Upvote Downvote

Fonar Corporation: What Investors Can Expect Going Forward

2018-03-31 seekingalpha
I never attempt to make money on the stock market. I buy on the assumption that they could. Reduction in the reimbursement rate for medical imaging will also affect profitability.
Upvote Downvote

Biolife Solutions - Solid Close To 2017 And Off To Strong Start In 2018; Significant Opportunity Lies Ahead

2018-03-29 seekingalpha
Sales growth of 34%/28% in FY2017/FY2016 achieved without any real impact from customer drug approvals; two customer approvals in 2H2017 and 15-20 Phase 3 trials bode well for future outlook.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 49803L109